These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interferon gamma-induced reduction in erbB-2 tyrosyl phosphorylation in human ovarian carcinoma cells.
    Author: Mishra S, Hamburger AW.
    Journal: Int J Cancer; 1994 Aug 15; 58(4):538-42. PubMed ID: 7914514.
    Abstract:
    Interferon, which inhibits growth of ovarian cancer cells in vivo and in vitro, decreases expression of erbB-2 protein in ovarian carcinoma cell lines. We now show that interferon-gamma (IFN-gamma) also decreases constitutive tyrosine phosphorylation of erbB-2 and inhibits erbB-2 kinase activity in an ovarian cancer cell line. SK-OV3 ovarian cancer cells, which over-express erbB-2, were treated with IFN-gamma for 0-72 hr. Immunoblot analysis revealed that IFN decreased the levels of tyrosyl phosphorylated erbB-2 24 hr after IFN treatment. Protein levels of erbB-2 were not changed until 72 hr post-treatment. Tyrosine kinase (TK) activity of immunoprecipitated erbB-2 for an exogenous substrate was decreased in IFN-treated cells. Total cellular protein tyrosine phosphatase (PTPase) activity for the epidermal growth factor receptor was not changed by IFN treatment. Our results suggest that the decreased levels of tyrosyl phosphorylated proteins observed after IFN treatment in SK-OV3 cells may be due to inhibition of erbB-2 kinase activity.
    [Abstract] [Full Text] [Related] [New Search]